Abstract
Voriconazole (VRCZ) is an azole antifungal agent that was developed to provide high antifungal activity against fluconazole (FLCZ)-resistant Candida, like non-albicans Canclida, as well as Aspergillus and Cryptococcus. Its pharmacokinetic properties are superior to those of FLCZ, including a high penetration into the central nervous system. It is also available as either an intravenous injection or an oral formulation, enabling the smooth transfer of patients from hospital to outpatient or home treatment and maximizing clinical efficacy and safety. VRCZ has been available for a wide variety of clinical purposes in Europe and the United States and was approved in Japan in April 2005.
